|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.68 USD | -8.77% |
|
-6.06% | +17.89% |
| 07-08 | Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise | MT |
| 07-08 | Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration | MT |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | -371M | -260M | -133M | -377M | -79.99M | ||||
Depreciation & Amortization - CF | 7.45M | 14.15M | 20.01M | 21.92M | 22.29M | ||||
Depreciation & Amortization, Total | 7.45M | 14.15M | 20.01M | 21.92M | 22.29M | ||||
(Gain) Loss on Sale of Investments - (CF) | -17.76M | -29.61M | -11.15M | -8.67M | -275M | ||||
Asset Writedown & Restructuring Costs | 155M | - | - | - | 14.51M | ||||
(Income) Loss On Equity Investments - (CF) | - | 25.5M | - | - | - | ||||
Stock-Based Compensation (CF) | 43.57M | 84.32M | 98.65M | 121M | 94.24M | ||||
Other Operating Activities, Total | 4.91M | -63.28M | -7.72M | 5.8M | 9.51M | ||||
Change In Accounts Receivable | -300M | 300M | -146K | - | - | ||||
Change In Accounts Payable | 818K | 2.37M | -7.58M | 1.81M | 6.04M | ||||
Change in Unearned Revenues | 348M | -35.92M | -160M | -36.52M | -135M | ||||
Change in Other Net Operating Assets | 62.28M | -14.82M | 50.83M | -75.51M | -1.64M | ||||
Cash from Operations | -66.27M | 22.53M | -149M | -347M | -345M | ||||
Capital Expenditure | -46.81M | -48.95M | -33.73M | -8.95M | -14.95M | ||||
Cash Acquisitions | 620K | - | - | - | -78K | ||||
Investment in Marketable and Equity Securities, Total | -248M | -412M | 106M | 194M | -106M | ||||
Cash from Investing | -294M | -461M | 71.84M | 185M | -121M | ||||
Long-Term Debt Issued, Total | - | - | - | - | - | ||||
Total Debt Issued | - | - | - | - | - | ||||
Long-Term Debt Repaid, Total | -2.12M | -2.29M | -2.25M | -485K | - | ||||
Total Debt Repaid | -2.12M | -2.29M | -2.25M | -485K | - | ||||
Issuance of Common Stock | 767M | 114M | 279M | 8.22M | 478M | ||||
Issuance of Preferred Stock | - | - | - | - | - | ||||
Other Financing Activities, Total | -8.82M | -188K | -631K | - | - | ||||
Cash from Financing | 756M | 112M | 276M | 7.74M | 478M | ||||
Net Change in Cash | 396M | -327M | 199M | -155M | 11.51M | ||||
Supplemental Items | |||||||||
Cash Interest Paid | 567K | 376K | 160K | 32K | - | ||||
Levered Free Cash Flow | -335M | 138M | -50.84M | -157M | -220M | ||||
Unlevered Free Cash Flow | -335M | 138M | -50.84M | -157M | -220M | ||||
Change In Net Working Capital | 191M | -300M | 25.46M | 30.43M | 82.1M | ||||
Net Debt Issued / Repaid | -2.12M | -2.29M | -2.25M | -485K | - |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















